title: Prospects of induced pluripotent stem cell technology in regenerative medicine.
abstract: Induced pluripotent stem (iPS) cells are derived from adult somatic cells via reprogramming with ectopic expression of four transcription factors (Oct3/4, Sox2, c-Myc and Klf4; or, Oct3/4, Sox2, Nanog, and Lin28), by which the resultant cells regain pluripotency, namely, the capability exclusively possessed by some embryonic cells to differentiate into any cell lineage under proper conditions. Given the ease in cell sourcing and a waiver of ethical opponency, iPS cells excel embryonic pluripotent cells in the practice of drug discovery and regenerative medicine. With an ex vivo practice in regenerative medicine, many problems involved in conventional medicine dosing, such as immune rejection, could be potentially circumvented. In this article, we briefly summarize the fundamentals and status quo of iPS-related applications, and emphasize the prospects of iPS technology in regenerative medicine.
authors.affiliation: Division of Bioengineering, School of Chemical and Biomedical Engineering, Nanyang Technological University. Singapore, Singapore.
authors.forename: Feng
authors.initials: F
authors.lastname: Zhang
authors.forename: Fudiman
authors.initials: F
authors.lastname: Citra
authors.forename: Dong-An
authors.initials: DA
authors.lastname: Wang
mesh_terms: D000818:Animals; D018929:Cell Culture Techniques / Q000379:methods; D002454:Cell Differentiation; D019070:Cell Lineage; D004475:Ectoderm / Q000502:physiology; D053595:Embryonic Stem Cells / Q000166:cytology; D004707:Endoderm / Q000502:physiology; D006801:Humans; D057026:Induced Pluripotent Stem Cells / Q000166:cytology*; D000090062:Kruppel-Like Factor 4; D008648:Mesoderm / Q000502:physiology; D051379:Mice; D012038:Regeneration; D044968:Regenerative Medicine / Q000379:methods*